Vivacy

What Vivacy does

Laboratoires VIVACY S.A.S., founded in 2007 and headquartered at 8 rue Bellini, 75116 Paris, is a French private manufacturer of injectable medical devices for regenerative aesthetic medicine. The company develops, produces, and distributes three injectable platforms — STYLAGE® hyaluronic acid-based dermal fillers (S, M, L, XL, XXL, Special Lips, Lips Plus, Hydro, Hydromax) for wrinkle correction, volume restoration, lip enhancement, and skin hydration; DESIRIAL® hyaluronic acid gels for female vulvovaginal restoration, the first injectable HA gel for intimate health launched in 2011; and NOVUMA® calcium hydroxyapatite biostimulators for collagen regeneration via Advanced BioSphere Technology. VIVACY also distributes REJURAN® polynucleotide skin boosters exclusively in Europe under a partnership with PharmaResearch (Korea) and offers KARTILAGE® viscosupplementation for knee osteoarthritis. Proprietary technologies include IPN-Like stabilization, the Skin3 Complex, and the Bi-FLEX® ergonomic syringe platform that uses 25% less plastic and was globally launched in September 2025.

The company manufactures at a dedicated facility in Archamps, France (ArchParc), holding Class III CE-mark certifications under notified body 0344 (STYLAGE/DESIRIAL), 2292 (NOVUMA, DESIRIAL Plus), and 2265 (REJURAN), with NOVUMA receiving MDR 2017/745 EU approval in 2025 and REJURAN receiving CE MDR clearance in 2024. Products are sold exclusively to qualified healthcare professionals — aesthetic doctors, plastic surgeons, dermatologists, and gynecologists — through a combination of seven wholly-owned European subsidiaries (France, Switzerland, Italy, UK, Spain, Benelux, Poland) and a certified distributor network spanning 85+ countries. Distribution includes exclusive European rights for PharmaResearch REJURAN and a global partnership with Burgeon Biotechnology for NOVUMA. Customer reach is cited at 250,000+ doctors worldwide.

VIVACY's revenue model is one-time medical device sales priced per syringe, with territory and order-volume-based determination via sales representatives and distributors. Supporting revenue and lock-in mechanisms include the VIVACY Academy training platform for HCP certification, the B.A.S.E. (Biology-Advanced Skin Education) clinical framework, and the Vivacy Security mobile app using RFID for product authentication. Marketing combines major aesthetic congress participation (AMWC Monaco, AMWC Dubai, IMCAS Asia), targeted social media, and a Beauty Hub/WWD China activation. The ownership is private and management-led, with Bertrand Frohly serving as President & CEO, Denis Couchourel as Scientific & Medical Director, and Frédéric Tranchepain as R&D Director; no external private equity or venture capital backing is disclosed.

Name

Vivacy

Legal name

Laboratoires Vivacy, S.A.S.

Website

https://vivacy.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Vivacy is a French private manufacturer of injectable hyaluronic acid dermal fillers (STYLAGE), intimate health gels (DESIRIAL), calcium hydroxyapatite biostimulators (NOVUMA), and exclusive European distributor of polynucleotide skin boosters (REJURAN), selling exclusively to aesthetic healthcare professionals across 85+ countries via European subsidiaries and a global distributor network.

Ownership category

akta.pro rank

Product category

Injectable Aesthetic Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)

akta.pro primary industry

Professional Skincare & Facial Treatments (CRABALAF)

Keywords

• Hyaluronic acid injectables
• Aesthetic medical devices
• Dermal fillers
• Collagen biostimulators
• Polynucleotide skin boosters

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Hyaluronic Acid Dermal Fillers: Sale of STYLAGE® range of injectable hyaluronic acid dermal fillers for facial aesthetics (wrinkle filling, volume restoration, lip enhancement, skin hydration). Includes products with and without lidocaine. Revenue generated from direct sales to healthcare professionals and through distribution network.
2. Intimate Health Products: Sale of DESIRIAL® and DESIRIAL® Plus hyaluronic acid injectable gels for female vulvovaginal restoration, addressing vaginal dryness, atrophy, and aesthetic concerns. First injectable HA gel for intimate health launched in 2011.
3. Collagen Biostimulators: Sale of NOVUMA® calcium hydroxyapatite injectable biostimulator for collagen stimulation and skin regeneration. Distributed through strategic partnership with Burgeon Biotechnology.
4. Polynucleotide Skin Boosters: Distribution of REJURAN® PN-based skin boosters from PharmaResearch (Korea's leading skin booster). Exclusive European distribution partnership. Made from highly purified wild salmon DNA fragments.
5. Medical Education & Training: VIVACY Academy provides training resources for healthcare professionals on product usage and injection techniques. Platform offers educational videos, webinars, scientific articles, and certification programs.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels8 records

Core offering

Vivacy develops, manufactures, and distributes injectable medical devices for regenerative aesthetic medicine. Its core offerings are hyaluronic acid-based dermal fillers (STYLAGE® range), hyaluronic acid gels for female intimate health (DESIRIAL®), calcium hydroxyapatite collagen biostimulators (NOVUMA®), and polynucleotide skin boosters (REJURAN® distributed in Europe). Products are CE-marked Class III medical devices sold exclusively to qualified healthcare professionals across 85+ countries.

Product overview

VIVACY is a French manufacturer of injectable medical devices for regenerative aesthetic medicine, operating since 2007. The product portfolio centers on three core injectable platforms: (1) STYLAGE® hyaluronic acid-based dermal fillers for facial aesthetics including wrinkle filling, volume restoration, lip enhancement, and skin hydration; (2) DESIRIAL® hyaluronic acid gels for female intimate health; and (3) NOVUMA® calcium hydroxyapatite biostimulators for collagen regeneration. VIVACY also distributes REJURAN® polynucleotides skin boosters exclusively in Europe. Supporting platforms include VIVACY Academy for physician training and Vivacy Security® app for product authentication. Key technologies include IPN-Like Technology, Skin3 Complex, Advanced BioSphere Technology, and the new Bi-FLEX® injection system.

Differentiator

Problem solved

Functional benefit

Brands

• STYLAGE: Premium range of hyaluronic acid-based dermal fillers for facial aesthetics, including S, M, L, XL, XXL variants, Special Lips, Lips Plus, and Hydromax skin booster products.
• DESIRIAL
• DESIRIAL PLUS
• NOVUMA
• REJURAN
• KARTILAGE
• VIVACY Academy
• MyVIVACY (Vivacy Security)
• Bi-FLEX

Products and services

• STYLAGE® Dermal Fillers Comprehensive range of hyaluronic acid-based dermal fillers for facial aesthetic treatments including STYLAGE® S and M for wrinkle filling, XL and XXL for volume restoration, Special Lips Lidocaine and Lips Plus for lip enhancement, and HYDRO and HYDROMAX for skin hydration. Sold to qualified healthcare professionals.
• STYLAGE® Hydromax Skinbooster Hyaluronic acid injectable gel skinbooster designed to improve skin quality, hydration, and elasticity using the Skin3 Complex that combines cross-linked HA, free HA, and sorbitol to promote cell regeneration across skin layers.
• REJURAN® PN Skin Booster Polynucleotide-based skin booster manufactured by Korea's PharmaResearch containing highly purified DNA fragments extracted from wild salmon, distributed exclusively in Europe by VIVACY. CE MDR 2024 certified (Class III medical device, CE 2265).
• NOVUMA® Collagen Biostimulator Calcium hydroxyapatite (CaHA) injectable biostimulator featuring Advanced BioSphere Technology with smooth round microspheres at 55-60% w/w concentration that stimulate natural collagen production to restore skin density, firmness, and long-lasting support. Class III medical device.
• DESIRIAL® Injectable Hyaluronic Acid Gel First injectable hyaluronic acid gel for female vulvovaginal restoration, treating vaginal dryness by restoring moisture and improving elasticity of vaginal tissues. CE-marked medical device (0344).
• DESIRIAL® Plus Hyaluronic acid injectable medical device specifically designed to improve the aesthetic appearance of the labia majora, treat atrophy or loss of volume, and rejuvenate vaginal tissues after menopause.
• KARTILAGE® Viscosupplementation Hyaluronic acid gel viscosupplementation medical device for treating knee osteoarthritis pain through intra-articular injection.
• VIVACY Academy Training Platform Online training platform exclusively for healthcare professionals offering expert-led trainings, key opinion leader content, monthly new videos, live webinars, facial and intimate aesthetics courses, and certification programs in multiple languages.
• Vivacy Security Mobile App Mobile application enabling healthcare professionals to verify product authenticity using RFID technology and access digitized instructions, including pre- and post-injection advice for patients. Available on iOS and Android.

Quantifiable outcome

• 91% of patients completely satisfied with hyaluronic acid injection results
• +6 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• PharmaResearch Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 22 April 2026VIVACY serves as exclusive European distribution partner for PharmaResearch's REJURAN® PN-based skin booster products. PharmaResearch completed a West European roadshow (April 22-30, 2026) across Benelux, UK, Switzerland introducing DOT™ technology to healthcare professionals. Plans continue for Italy (May), Poland (June), France (September), Germany (H2 2026) rollout.
• Beauty Nova Tech Hub / WWD ChinaminorGTM or Marketing Partner · 3 March 2026Partnership through Beauty Hub platform in Shanghai's Jing'an district, a global beauty innovation platform. Vivacy introduced its Stylage L product line through this platform. The platform supports international collaboration through market-entry guidance, industry forums, and brand showcases. Includes Global Beauty Innovation Network and 'Beauty for Future' initiative with 66 brands.
• Burgeon BiotechnologycoreStrategic or Co-development Partner · 26 March 2025Strategic collaboration combining VIVACY's expertise in hyaluronic acid dermal fillers with Burgeon's innovative NOVUMA calcium hydroxyapatite biostimulator. This partnership enables VIVACY to enter the fast-growing biostimulants market, offering physicians complementary technologies for skin regeneration. Bertrand Frohly (President & CEO, VIVACY) stated NOVUMA answers growing demand for skin quality and regeneration.
• Levent Mete Özgürbüz (Burgeon Biotechnology Founder)coreStrategic or Co-development Partner · 26 March 2025Founder of Burgeon Biotechnology, instrumental in establishing strategic partnership for NOVUMA global distribution. Partnership aims to lead the industry and deliver innovative solutions, strengthening and expanding product comprehensiveness and effectiveness.

Scale indicators13 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Prollenium Medical Technologies: Canadian maker of the Revanesse line of HA dermal fillers, sold through physician channels in North America and international markets. Comparable mid-sized specialist competing on HA filler technology differentiation.
• Teoxane: Swiss specialist in hyaluronic acid dermal fillers (Teosyal range), a fellow European-based mid-sized HA injector with comparable physician-channel GTM and a portfolio spanning fillers, skin boosters, and cosmeceuticals. Closest like-for-like private peer to VIVACY.
• Sinclair Pharma: Aesthetic medicine specialist with HA fillers (MaiLi), collagen stimulators (Ellansé), and bio-remodeling (Profhilo). Comparable mid-sized, Europe-anchored portfolio across multiple injectable modalities — similar diversification strategy to VIVACY's HA + CaHA + PN stack.
• Galderma: Global dermatology and aesthetic injectable leader, with the Restylane hyaluronic acid filler portfolio directly competing against STYLAGE. Galderma also markets Sculptra biostimulator and is the most direct large-scale competitor to VIVACY in physician-dispensed HA injectables.
• Croma-Pharma: Austrian family-owned manufacturer of HA-based injectables (Princess fillers) and PRF systems, sold through a physician-focused network across Europe and select global markets. Closely comparable in scale, ownership structure, and European distribution footprint to VIVACY.
• Merz Aesthetics: Sells Belotero hyaluronic acid fillers and Radiesse calcium hydroxyapatite biostimulator, the closest single competitor to VIVACY's combined HA + CaHA portfolio. Targets the same physician channels with comparable claims around natural results and longevity.
• PharmaResearch: Korean manufacturer of REJURAN polynucleotide skin boosters. Counterpart supplier to VIVACY for the European market and a direct competitor in PN-based regenerative aesthetics in Asia; the partnership relationship makes it both a peer and a strategic dependency.

Emerging players

• Hugel: Korean aesthetic and neurotoxin company with expanding HA filler (Chaeum) and biostimulator offerings. Comparable trajectory to VIVACY as an Asia-rooted specialist expanding internationally across multiple injectable modalities.
• LG Chem Life Sciences: Sells Yvoire line of HA dermal fillers and is expanding its aesthetics footprint globally. Comparable mid-tier HA injectable competitor with growing investments in biostimulator-adjacent categories and physician-channel distribution.

Broad incumbents

• AbbVie / Allergan Aesthetics: Owner of the Juvéderm HA filler franchise, the global #1 in aesthetic injectables. Overlaps directly with STYLAGE in facial volumization and lip enhancement, and competes for the same dermatologists and plastic surgeons, but as part of a much broader pharmaceutical and aesthetics portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCkYK7mHfG637Se0SY_kQIQg
• Facebookfacebook.com/laboratoiresvivacy
• LinkedInlinkedin.com/company/laboratoires-vivacy-sas/?viewAsMember=true
• Instagraminstagram.com/laboratoiresvivacy
• Xx.com/VivacyColombia

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vivacy